Windtree Therapeutics
The provided page for windtreetx.com returns a Cloudflare Error 526 indicating the origin web server's SSL certificate could not be validated. No company content or product information was available on the supplied page.
Industries
biotechnology
health-care
pharmaceutical
wellness
Nr. of Employees
small (1-50)
Windtree Therapeutics
Warrington, Pennsylvania, United States, North America
Patents
Products
Istaroxime
A first-in-class, novel asset and dual-mechanism drug candidate (SERCA2a activator and Na+/K+-ATPase inhibitor) in Phase 2 clinical development for cardiogenic shock and acute heart failure.
Aerosol Delivery System (ADS) Technology Platform
Windtree's proprietary ADS is designed to aerosolize KL4 surfactant by pumping it through a heated capillary to yield a dense aerosol with a defined particle size suitable for respiration in premature infants.
Istaroxime
A first-in-class, novel asset and dual-mechanism drug candidate (SERCA2a activator and Na+/K+-ATPase inhibitor) in Phase 2 clinical development for cardiogenic shock and acute heart failure.
Aerosol Delivery System (ADS) Technology Platform
Windtree's proprietary ADS is designed to aerosolize KL4 surfactant by pumping it through a heated capillary to yield a dense aerosol with a defined particle size suitable for respiration in premature infants.